SUPPLEMENTAL INFORMATION

3 Months Ended

Mar. 31, 2024

Geographic Areas, Long-Lived Assets [Abstract]

Supplemental information

SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

	March 31, 2024		December 31, 2023
	Unaudited		Audited
United States	$	45,358	$	41,634
Israel	8,290		8,317
Switzerland	10,940		7,733
Others	6,240		5,179
Total long lived assets	$	70,828	$	62,863

Restructuring

In November 2023, the Company announced a series of actions to strengthen and optimize its business operations to support near-term growth drivers and long-term value creation. The plan included a reduction in headcount of approximately 200 employees or 13% of the Company's then current workforce. The Company incurred restructuring costs (including severance pay, garden leave payments, etc.) in the amount of $2,031 and $6,231 for the three months ended March 31, 2024 and the year ended December 31, 2023, respectively, as follows:

	Three months ended March 31,		Year ended December 31, 2023
	2024
	Unaudited		Audited
Cost of revenues	$	52	$	262
Research, development and clinical studies	275		2,070
Sales and marketing	1,539		2,404
General and administrative	164		1,495
Total restructuring cost	$	2,031	$	6,231
Restructuring costs paid during the period	$	5,128	$	2,753

These restructuring costs were offset by accrual reversals for the three months ended March 31, 2024 and the year ended December 31, 2023 in the amount of $369 and $3,041, respectively, which relate to the terminated employees' exits from the Company’s cash incentive plans. These restructuring costs were further offset by forfeited equity-based compensation expense reversals for the three months ended March 31, 2024 and the year ended December 31, 2023 in the amount of $1,661 and $9,313, respectively, which relate to the terminated employees' exits from the Company’s equity incentive plan.